Estudio gammagráfico de la disfunción de las glándulas salivales en pacientes con cáncer diferenciado de tiroides tratados con yodo radiactivo


  1. Ariyan S. Cancer of the head and neck. 1st Edition. St. Louis: Mosby; 1987.
  2. Becker DV, Sawin CT. Radioiodine and thyroid disease: the beginning. Semin Nucl Med 1996; 26:155-64.
  3. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418-28.
  4. Doi SA, Woodhouse NJ. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer. Clin Endocrinol (Oxf) 2000; 52:765-73.
  5. Allweiss P, Braunstein GD, Katz A, Waxman A. Sialadenitis following I131 therapy for thyroid carcinoma: concise communication. J Nucl Med 1984; 25:755-8.
  6. Rosário PW, Maia FF. Sialoadenite após terapia ablativa com altas doses de radioiodo no tratamento do carcinoma diferenciado de tireóide. Endocrinol Metab 2004; 48:241-5.
  7. Hyer S, Kong A, Pratt B, Harmer C. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol (R Coll Radiol) 2007; 19:83-6.
  8. Almeida JP, Sanabria AE, Nobrega E, Kowalski LP. Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer. Head & Neck 2011; 33:686-90.
  9. Klubo-Gwiezdzinska J, Van Nostrand D, Burman KD et al. Salivary gland malignancy and radioiodine therapy for thyroid cancer. Thyroid 2010; 20:647-51.
  10. Newkirk KA, Ringel MD, Wartofsky L, Burman KD. The role of radioactive iodine in salivary gland dysfunction. Ear Nose Throat J 2000; 79:460-8.
  11. Macioszek A, Baczyk M, Kopec T, Sowinski J. Salivary gland damage after 131I therapy in patients with differentiated thyroid cancer. Endocrynol Pol 2008; 59:403-10.
  12. Caglar M, Tuncel M, Alpar R. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Clin Nucl Med 2002; 27:767-7.
  13. Lee SL. Complications of radioactive iodine treatment of thyroid carcinoma. J Natl Compr Canc Netw 2010; 8:1277-86.
  14. Van Nostrand D. Sialoadenitis secondary to ¹³¹I therapy for well-differentiated thyroid cancer. Oral Dis 2011; 17:154-61.
  15. Rosário PW, Maia FF, Barroso A et al. Sialoadenitis following ablative therapy with high doses of radioiodine for treatment of differentiated thyroid cancer. Arq Bras Endocrinol Metabol 2004; 48:310-4.
  16. Nakada K, Ishibashi T, Takei T et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med 2005; 46:261-6.
  17. Mandel L, Liu F. Salivary gland injury resulting from exposure to radioactive iodine: case reports. J Am Dent Assoc 2007; 138:1582-7.
  18. De Groot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990; 71:414-24.
  19. Grewal RK, Larson SM, Pentlow CE et al. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med 2009; 50:1605-10.
  20. Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid 2003; 13:265-71.
  21. Klutmann S, Bohuslavizki KH, Kroger S, et al. Quantitative salivary gland scintigraphy. J Nucl Med Technol 1999; 27:20-26
  22. Shall GL, Anderson LG, Wolf RO, et al. Xerostomia in Sjögren’s syndrome: evaluation by sequential salivary scintigraphy. JAMA 1971; 216:2109-16.
  23. Solans R, Bosch JA, Glofré P, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 2001; 42:738-43.